BTNL9 exerts anti-cancer effects by inhibiting CDC20 to induce G2/M arrest in pancreatic cancer

Figure 1 The expression level of BTNL9 in pancreatic cancer and its relationship with prognosis. A: Differential expression of BTNL9 in pancreatic cancer (PC) and adjacent non-cancerous tissues across five data sets from the Gene Expression Omnibus; B: The expression of BTNL9 in cancer and normal pancreas was different analyzed in Gene Expression Profiling Interactive Analysis; C: The expression level of BTNL9 in the tissue microarray detected by immunohistochemistry (the odd-numbered columns are tumor tissues, and the even-numbered columns are adjacent normal tissues); D: Expression level of BTNL9 in 7 cases with PC in our hospital; E: Based on The Cancer Genome Atlas and tumor microarray data, the prognostic differences of different BTNL9 expression levels; F: The predictive efficacy of BTNL9 expression for overall survival; G: The expression of BTNL9 was an independent factor affecting overall survival in patients with PC. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001. TCGA: The Cancer Genome Atlas; GTEx: Genotype-Tissue Expression Project; TMA: Tissue microarray; AUC: Aera under the curve; HR: Hazard ratio; CI: Confidence interval; AJCC: American Joint Committee on Cancer.